Inhaled Innovation | Explore MannKind's pioneering inhaled therapeutics, focusing on Tyvaso DPI and Afrezza, as the company navigates growth and challenges in specialized markets. |
Pipeline Potential | Delve into MannKind's promising pipeline, including NTM and IPF treatments, set to begin trials in June 2024, potentially reshaping the company's market position. |
Financial Trajectory | Learn about MannKind's robust 63% year-over-year revenue growth, driven by Tyvaso DPI, with 2024 revenue estimates increased to $266 million from $259.1 million. |
Market Outlook | Analyst price targets range from $5.00 to $6.50, reflecting optimism tempered by pipeline dependencies and interest expense concerns in a competitive landscape. |
Chỉ số cần so sánh | MNKD | Lĩnh vực Ngành- Số liệu trung bình từ một nhóm lớn các công ty Y Tế liên quan thuộc ngành | Mối quan hệ Mối quan hệMNKDCông TyLĩnh vực | |
|---|---|---|---|---|
Tỉ số P/E | 51.5x | −3.4x | −0.7x | |
Tỷ Lệ PEG | 0.35 | 0.10 | 0.00 | |
Giá/G.Trị Sổ Sách | −30.7x | 1.8x | 2.6x | |
Giá / Doanh Số 12T | 5.6x | 75.2x | 3.4x | |
Tăng (Mục Tiêu của Nhà Phân Tích) | 82.1% | 329.6% | 38.2% | |
Giá Trị Hợp Lý Tăng | Mở Khóa | 4.9% | 4.7% | Mở Khóa |